Leerink Partnrs Has Strong Estimate for INSP FY2024 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Research analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for Inspire Medical Systems in a report issued on Monday, November 4th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of $1.38 for the year, up from their prior estimate of $0.79. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $0.75 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at $0.41 EPS, Q3 2025 earnings at $0.48 EPS, FY2025 earnings at $1.76 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $3.63 EPS.

A number of other brokerages have also weighed in on INSP. KeyCorp cut their target price on shares of Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Piper Sandler restated an “overweight” rating and set a $260.00 price target (up previously from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday. Wells Fargo & Company raised their price objective on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the company an “equal weight” rating in a research note on Tuesday. Stifel Nicolaus restated a “hold” rating and issued a $200.00 target price (up previously from $170.00) on shares of Inspire Medical Systems in a report on Tuesday. Finally, Leerink Partners lifted their price target on Inspire Medical Systems from $167.00 to $197.00 and gave the company a “market perform” rating in a research note on Tuesday, September 10th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $227.75.

Inspire Medical Systems Stock Up 6.3 %

INSP stock opened at $211.63 on Thursday. The company’s 50-day moving average price is $201.94 and its two-hundred day moving average price is $179.94. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $257.40. The firm has a market cap of $6.31 billion, a P/E ratio of 197.79 and a beta of 1.36.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.54. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.51%. The company had revenue of $203.20 million during the quarter, compared to analysts’ expectations of $197.59 million. During the same quarter in the previous year, the business posted ($0.29) earnings per share. Inspire Medical Systems’s quarterly revenue was up 32.6% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SouthState Corp bought a new stake in Inspire Medical Systems in the 2nd quarter valued at about $27,000. Farther Finance Advisors LLC increased its stake in shares of Inspire Medical Systems by 1,158.3% in the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after purchasing an additional 139 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Inspire Medical Systems by 559.3% in the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after purchasing an additional 151 shares in the last quarter. Quarry LP raised its position in shares of Inspire Medical Systems by 105.4% in the second quarter. Quarry LP now owns 343 shares of the company’s stock valued at $46,000 after purchasing an additional 176 shares during the period. Finally, Daiwa Securities Group Inc. purchased a new stake in shares of Inspire Medical Systems during the 2nd quarter valued at approximately $53,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 800 shares of Inspire Medical Systems stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the sale, the director now directly owns 23,140 shares in the company, valued at $5,090,800. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares in the company, valued at approximately $5,090,800. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Randy Ban sold 4,861 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the completion of the transaction, the insider now owns 3,056 shares in the company, valued at approximately $576,208.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,692 shares of company stock worth $1,099,207 in the last quarter. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.